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Selective inhibition of HDAC8 decreases
neuroblastomagrowth in vitro and in vivo and enhances
retinoic acid-mediated differentiation
I Rettig1, E Koeneke1, F Trippel2, WC Mueller3, J Burhenne4, A Kopp-Schneider5, J Fabian1, A Schober6, U Fernekorn6, A von Deimling7,
HE Deubzer1,8,9, T Milde1,8, O Witt1,8 and I Oehme*,1
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic acid and histone deacetylase
(HDAC) inhibitors, are of particular interest. HDAC inhibitors are currently under investigation for the treatment of a broad spectrum
of cancer diseases. However, one clinical drawback is class-specific toxicity of unselective inhibitors, limiting their full anticancer
potential. Selective targeting of individual HDAC isozymes in defined tumor entities may therefore be an attractive alternative
treatment approach. We have previously identified HDAC family member 8 (HDAC8) as a novel target in childhood neuroblastoma.
Using small-molecule inhibitors, we now demonstrate that selective inhibition of HDAC8 exhibits antineuroblastoma activity
without toxicity in two xenograft mouse models of MYCN oncogene-amplified neuroblastoma. In contrast, the unselective HDAC
inhibitor vorinostat was more toxic in the same models. HDAC8-selective inhibition induced cell cycle arrest and differentiation
in vitro and in vivo. Upon combination with retinoic acid, differentiation was significantly enhanced, as demonstrated by elongated
neurofilament-positive neurites and upregulation of NTRK1. Additionally, MYCN oncogene expression was downregulated in vitro
and tumor cell growth was markedly reduced in vivo. Mechanistic studies suggest that cAMP-response element-binding protein
(CREB) links HDAC8- and retinoic acid-mediated gene transcription. In conclusion, HDAC-selective targeting can be effective in
tumors exhibiting HDAC isozyme-dependent tumor growth in vivo and can be combined with differentiation-inducing agents.
Cell Death and Disease (2015) 6, e1657; doi:10.1038/cddis.2015.24; published online 19 February 2015
The development of neuroblastoma, the most common
extracranial solid tumor of childhood, is hypothesized to be
related to maturation defects of neural crest-derived precursor
cells of the peripheral sympathetic nervous system. The long-
term overall survival probability of high-risk neuroblastoma
patients iso50%. In addition, chemotherapy-treated patients
struggle with therapy-related immediate and long-term toxi-
cities (reviewed in Brodeur1). Thus, more neuroblastoma-
optimized therapy approaches aiming at oncogenic molecular
targets, for example, affecting neuroblastoma cell maturation
and proliferation, are believed to improve therapeutic efficacy,
reduce toxicity and avoid long-term side effects.2 Small
molecules, which influence gene transcription, for example,
histone deacetylase (HDAC) inhibitors, are known to induce
maturation of differentiation-defective tumor cells, such as
neuroblastoma cells (reviewed in Witt et al.3).
The human family of HDACs is grouped into four classes
based on their homology to yeast HDACs. Three of the four
classes (class I, II and IV) have a zinc-dependent catalytic
mechanism and are the so-called classical HDACs. HDAC
family member 8 (HDAC8) together with HDAC1, 2 and 3
compose class I.4 HDACs remove acetyl groups from lysine
residues of numerous nuclear and cytosolic proteins, affecting
gene transcription as well as many cellular pathways
(Choudhary et al.5 and Glozak et al.6 and reviewed in Marks
et al.7). Small-molecule inhibitors of HDAC enzymatic activity
bind to the highly conserved catalytic domain and hence
unselectively inhibit the activity of all zinc-dependent HDACs.
Vorinostat (SAHA: suberoylanilide hydroxamic acid) was the
first HDAC inhibitor to be approved for clinical use by the FDA
for the treatment of refractory cutaneous T-cell lymphoma.8 In
several clinical trials, vorinostat was active against leukemia
1Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 2Department of Pediatric Surgery, Dr. von Hauner
Children's Hospital, Ludwig-Maximilians-University Munich, Munich, Germany; 3Department of Neuropathology, Institute for Pathology, University of Leipzig, Leipzig,
Germany; 4Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, Germany; 5Department of Biostatistics, German
Cancer Research Center (DKFZ), Heidelberg, Germany; 6Ilmenau University of Technology, Institute for Micro- and Nanotechnologies, Ilmenau, Germany; 7Department of
Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg, and Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ),
Heidelberg, Germany and 8Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Heidelberg, Germany
*Corresponding author: I Oehme, Clinical Cooperation Unit Pediatric Oncology (G340), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg
69120, Germany. Tel: +49 6221 423388; Fax: +49 6221 423277; E-mail: i.oehme@dkfz.de
9Current adress: Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Charité - University Medicine Berlin, CVK, CC17, Augustenburger Platz 1,
13353 Berlin
Received 29.10.14; revised 29.12.14; accepted 12.1.15; Edited by M Agostini
Abbreviations: 13-cis RA, 13-cis retinoic acid; Ac-H4, acetylated histone 4; Ac-SMC3, acetylated structural maintenance of chromosomes 3 protein; Ac-tubulin,
acetylated tubulin; AMC, Academic Medical Center; AP, alkaline phosphatase; ATRA, all-trans retinoic acid; Cpd2, compound 2 (1-naphthohydroxamic acid); CREB, cAMP-
response element-binding protein; GEO, Gene Expression Omnibus; GGT, gamma-glutamyltransferase; GPT, glutamic pyruvic transaminase; HDAC, histone deacetylase;
HDAC8, HDAC family member 8; H&E, hematoxylin and eosin; INSS, International Neuroblastoma Staging System; MTD, maximum tolerable dose; NEF, neurofilament;
NTRK1, neurotrophic tyrosine kinase receptor type 1; OT, glutamic oxaloacetic transaminase; PBMC, peripheral blood mononuclear cells; P-H3, phosphorylated histone 3;
SAHA, suberoylanilide hydroxamic acid; TrkA, tropomyosin receptor kinase A; TSA, trichostatin A
Citation: Cell Death and Disease (2015) 6, e1657; doi:10.1038/cddis.2015.24
& 2015 Macmillan Publishers Limited All rights reserved 2041-4889/15
www.nature.com/cddis
and lymphoma, but rather modestly effective against solid
tumors.9 As HDACs are involved in numerous essential
cellular processes, the clinical use of broad-spectrum
HDAC inhibitors is associated with dose-limiting side effects
such as thrombocytopenia, fatigue, nausea, diarrhea and
anorexia (reviewed in Lane and Chabner9 and Witt et al.10).
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Because similar toxicity profiles have been independently
observed in many clinical trials involving HDAC inhibitors, it is
believed that these are drug class-specific side effects, which
limit their full anticancer potential. Thus, there is an ongoing
debate in the field of HDAC inhibitor development as to whether
selective inhibitors targeting only a single HDAC family member
that drives tumor growth and survival would result in a larger
therapeutic window and greater efficacy compared with broad-
spectrum inhibitors currently in clinical use.11 So far, in vivo
proof of concept demonstrating that superior antitumoral activity
using an HDAC-isozyme-selective inhibitor can be achieved is
lacking. In this regard, HDAC family member 8 appears to be an
attractive target, as crystal structure analysis revealed a unique
secondmetal binding site in close proximity to themain catalytic
domain,12 which distinguishes this HDAC isozyme from the
other classical deacetylases. This finding led to the design of
linkerless hydroxamic acid-based inhibitors13,14 that fit in this
secondary pocket and display a much higher selectivity for
HDAC8 over the other classical HDACs. We have previously
shown that the expression of HDAC8 correlates with advanced
tumor stage and poor outcome in neuroblastoma.15 Here, we
verify small-molecule inhibition of HDAC8 as a novel therapeu-
tic strategy alone and as a potent enhancer of retinoic acid-
mediated differentiation and propose the cAMP-response
element-binding protein (CREB) as a link between HDAC8
and retinoic acid-mediated gene transcription.
Results
HDAC8 as a neuroblastoma drug target in vivo. We have
recently demonstrated that knockdown and inhibition of
HDAC8 in neuroblastoma cell cultures induced cell cycle
arrest and differentiation.15 The aim of the current study was
to evaluate HDAC8 as a potential drug target in vivo. Before
this, we investigated HDAC8 expression in human tumor
samples. We reanalyzed publically available expression data
from the AMC (Academic Medical Center) cohort (GEO
accession no. GSE16476) of neuroblastoma patients using
the web-based R2 microarray database (http://r2.amc.nl).16
The expression of HDAC8 significantly differed between the
tumor stages. HDAC8 expression levels significantly corre-
lated with INSS (International Neuroblastoma Staging Sys-
tem) stage 4 and poor overall survival (Supplementary
Figures 1A and B). These results confirm our previously
published observation with human tumor samples from the
German neuroblastoma trial.15 We additionally tested the
HDAC8 protein expression in a diversity of neuroblastoma
cell lines. All neuroblastoma cell lines used were HDAC8
positive, independent of MYCN oncogene amplification
status. In contrast, infant fibroblasts displayed much lower
HDAC8 protein levels (Supplementary Figure S1C). To
confirm HDAC8 as a potential therapeutic target in vivo, we
examined the influence of HDAC8 knockdown on tumor
growth in a neuroblastoma xenograft mouse model. For this
purpose, we used BE(2)-C, a well-established cell line
representing a relatively chemotherapy-resistant, highly
aggressive, MYCN-amplified and p53 mutant neuroblastoma
cell model. Cells transiently transfected with either negative
control or HDAC8 targeting siRNA were xenografted sub-
cutaneously into athymic mice. The specificity of the used
siRNA was previously defined.15 HDAC8 depletion delayed
tumor growth with a significant difference in tumor weight at
day 9 after tumor transplantation (Figure 1a). HDAC8 was
clearly depleted at the beginning. However, owing to the
transient nature of the transfection, the expression of HDAC8
increased again over time (Supplementary Figure S1D). This
result supported our hypothesis to use HDAC8 as a
neuroblastoma drug target in vivo.
HDAC8-selective inhibitors display antineuroblastoma
activity in vitro. To inhibit specifically HDAC8 activity in
neuroblastoma, we decided to use and compare two
structurally divergent HDAC8 inhibitors, which are both
reported to be selective for HDAC8: Compound 2 (Cpd2; 1-
naphthohydroxamic acid13) and PCI-34051.14 For PCI-
-34051, two more stable variants exist: PCI-48000 and
PCI-48012. A comparison of the compounds and concentra-
tions applied is shown in Figure 1b. We confirmed HDAC8
selectivity of Cpd2 and PCI-34051 using in vitro cell-free
biochemical assays of all classical HDACs 1–11
(Supplementary Table 1). This determined HDAC6 and
HDAC1 as potential off-target HDACs at concentrations
above 75 μM for Cpd2 and above 30 μM for PCI-34051.
Thus, acetylation levels of HDAC6 or HDAC1 substrates can
be used as an indicator for unselective HDAC family inhibition
for the two HDAC8-selective compounds. We therefore
established working concentrations for the selective use of
the inhibitors on neuroblastoma cells at 40 μM for Cpd2 and
4 μM for PCI-34051 and PCI-48000. We confirmed the
HDAC8-selective inhibition under these conditions: (i)
increase in whole lysine acetylation levels (Figure 1c and
Supplementary Table 2), (ii) increase in acetylation level of
Figure 1 Characterization of HDAC8 inhibitors in vitro. (a) In vivo validation of HDAC8 as a drug target. Tumor weight of explanted BE(2)-C neuroblastoma xenografts after
siRNA-mediated transient knockdown of HDAC8 or negative control (NC) in NMRI Foxn1 nude mice (cohorts of 20 animals each). Cells were transplanted 48 h after knockdown.
Data are represented as mean tumor weight± S.E.M. Mann Whitney was used for statistics (***Po0.001). (b) Summary of the HDAC8 inhibitors used in the study. The chemical
structures of linkerless hydroxamic acid-based inhibitors selective for HDAC8, Cpd2 and PCI-34051 are shown. PCI-48000 and PCI-48012 are more stable variants of PCI-34051.
(c) Flow cytometric analysis of intracellular whole lysine acetylation levels of IMR-32 cells. Cells were treated with HDAC8 inhibitors Cpd2 (40 μM) and PCI-48000 (4 μM) for 24 h.
TSA (trichostatin A, 150 nM) was used as positive control. Solvent: DMSO control. Blank: secondary antibody only. (d) Left panel: western blot analysis of histone 4, α-tubulin and
SMC3 acetylation levels in BE(2)-C cells treated with increasing concentrations of Cpd2 (0, 40, 100 and 200 μM), PCI-34051 (0, 4, 30 and 100 μM) and PCI-48000 (0, 4, 20 and
100 μM). Actin served as a loading control. Right panel: Western blot analysis of histone 4 acetylation, α-tubulin acetylation and SMC3 acetylation in HDAC8-depleted (siH8)
versus negative control siRNA (NC)-transfected BE(2)-C cells. (e) Determination of total cell numbers 6 days after treatment of neuroblastoma cell lines (MYCN amplified:
BE=BE(2)-C, IM= IMR-32 and Ke= Kelly; non-amplified: SY= SH-SY5Yand SK=SK-N-AS), medulloblastoma cell lines (UW=UW-288-2, DA=DAOYand ON=ONS76)
and proliferative infant fibroblasts (FB), as well as astrocytes (As) with HDAC8 inhibitors Cpd2 (40 μM), PCI-34051 (4 μM) and PCI-48000 (4 μM). Cell count was normalized to
solvent-treated cells. T-test was used for statistics. *Po0.0001, bars represent mean values and error bars represent S.E.M.
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the HDAC8 substrate core cohesion complex protein SMC317
(Figure 1d), (iii) absence of HDAC6 substrate acetylation
(tubulin;18 Figure 1d and Supplementary Figure S2) and (iv)
absence of HDAC1-3 substrate acetylation (histone 4;19
Figure 1d and Supplementary Figure S2). Treatment with the
pan-HDAC inhibitor TSA (trichostatin A), which was used as a
control for unselective HDAC inhibition, resulted in a much
stronger induction of global lysine acetylation (Figure 1c and
Supplementary Table 2). This is in line with the higher amount
of acetylated substrates as a consequence of inhibition of
multiple HDACs. As predicted, increasing concentrations of
Cpd2 and PCI-34051, far above their IC50 values, displayed
HDAC6 off-target activity and induced tubulin acetylation
(Figure 1d).
The treatment of a panel of MYCN-amplified as well as
MYCN-single-copy neuroblastoma cell lines with HDAC8
inhibitors for 6 days significantly decreased cell numbers. Of
note, medulloblastoma cell lines were less susceptible
compared with neuroblastoma cells. Untransformed cells
(infant fibroblasts and astrocytes) hardly responded to the
treatment (Figure 1e). So far, these results point towards
HDAC8 as a promising and selective target for neuroblastoma
treatment.
HDAC8-selective inhibitors display antineuroblastoma
activity in vivo. To determine the in vivo efficacy of
HDAC8-selective inhibitors in neuroblastoma, we started to
characterize the inhibitors for in vivo use. We first determined
toxicity profiles, maximum tolerable doses (MTDs) and
plasma levels of the two HDAC8-selective inhibitors Cpd2
and PCI-48012 for application in mice in vivo. We chose the
latter compound as a more in vivo stable variant of PCI-48000
with improved pharmacokinetic properties (Figure 1b). Both
inhibitors were intraperitoneally injected into NMRI Foxn1
nude mice in increasing doses from 40 up to 400mg/kg
per day for 2 × 5 days. Each dose was tested in a cohort of
three animals. Resulting MTDs were validated within cohorts
of eight animals for each inhibitor. Dose-limiting toxicities
(DLTs) were determined by monitoring body weight, where a
reduction of ≥20% from starting body weight indicated
toxicity. Additional experiments performed to check for toxicity
included clinical chemistry and hematological blood para-
meters, as well as histological examination of a panel of
organs for toxicity using hematoxylin and eosin (H&E) stain
after killing the animals. As a reference, the blood of 12
untreated NMRI Foxn1 nude mice was analyzed. In these
studies, we determined the MTD for HDAC8 inhibitors Cpd2
at 50mg/kg per day and for PCI-48012 at 40mg/kg per day.
At these concentrations, neither body weight (Figure 2a) nor
blood parameters were critically changed according to clinical
toxicity criteria (Table 1). DLTs of Cpd2 included weight loss
and signs of liver toxicity, as evidenced by elevated plasma
liver enzymes and detection of necrotic areas on histological
liver examination. DLTs of PCI-48012 included severe
inflammation of the intestine at organ examination, but no
noticeable changes in blood parameters. Pharmacokinetic
studies after intraperitoneal administration of the inhibitors
identified the half-life of Cpd2 to be ~ 15min, with a plasma
peak concentration of ~ 30 μM, matching the in vitro HDAC8
IC50 of 34 μM (Figure 2b). PCI-48012 has a half-life of ~ 1 h,
with a plasma peak concentration of 8.24 μM after adminis-
tration of a single dose of 100mg/kg, suggesting that the
MTD of 40mg/kg results in therapeutic plasma levels above
the HDAC8 in vitro IC50, but still in the range of selectivity. As
a pharmacodynamic marker for HDAC8 inhibitory action
in vivo, we analyzed lysine acetylation levels in peripheral
blood mononuclear cells (PBMC) after intraperitoneal admin-
istration of Cpd2 and PCI-48012 at MTD concentrations
(Supplementary Table 2). HDAC8 selectivity was further
controlled by the absence of tubulin acetylation and absence
of histone 4 acetylation in PBMC (Figure 2c). Vorinostat was
used as a control for unselective HDAC inhibition. The MTD
of vorinostat in mice (150mg/kg per day) is well established
and was taken from the published literature.20
Next, we determined the in vivo efficacy of HDAC8-selective
inhibition in neuroblastoma xenograft mouse models.
Because the pharmacokinetic studies revealed a relatively
short half-life for Cpd2, we subsequently used PCI-48012 for
treatment efficacy studies. One week after tumor cell injection,
mice established a palpable tumor mass and the animals were
then randomly assigned to treatment and control cohorts.
Treatment with PCI-48012 significantly delayed tumor growth
compared with solvent-treated control group. Moreover,
HDAC8-selective inhibition delayed neuroblastoma tumor
growth more efficiently (BE(2)-C model; Figure 2d) or equally
efficiently (IMR-32model; Figure 2e) compared with vorinostat
treatment. Whereas vorinostat treatment induced clear signs
of toxicity, such as diarrhea and weight loss at the applied
dose, HDAC8-selective inhibitor treatment was well tolerated
(Figure 2f).
HDAC8-selective inhibition promotes differentiation,
delays cell proliferation and induces cell death in vitro
and in vivo. We have previously demonstrated that HDAC8
depletion of neuroblastoma cells via siRNA transfections
resulted in an upregulation of markers for differentiation (NEF
and NTRK1) as well as G0/G1 cell cycle arrest with p21WAF1/
CIP1 upregulation. In line with our previous data, all three
HDAC8 inhibitors induced morphological changes pointing
towards neuronal differentiation, which was associated with
an increase in neurofilament (Figure 3a) and TrkA protein
expression (Figure 3b). In addition, all HDAC8 inhibitors used
delayed neuroblastoma population growth (Figure 3c) and
induced the cell-cycle inhibitor p21WAF1/CIP1 (Figure 3d).
Furthermore, differentiation and proliferation disruption was
followed by cell death (Figure 3e).
Corresponding to these in vitro data, quantitative immuno-
histochemical analysis of the dissected tumor material from
the HDAC8-inhibitor-treated mice revealed an increase in
neurofilament-positive tumors (7/12=58.3%) compared with
control groups (1/12= 8.3%), and a significantly lower amount
of cells positive for phosphorylated histone H3, a marker for
mitosis (Figure 4).
Consistent with the cell culture results, induction of
differentiation was also accompanied by induction of cell
death in vivo. The amount of tumor cells positive for active
caspase-3 was significantly increased. Taken together,
selective inhibition of HDAC8 enhanced differentiation,
reduced tumor growth and induced cell death in vitro and
in vivo.
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Figure 2 Characterization of HDAC8 inhibitors in vivo. (a) NMRI Foxn1 nude mice were treated with different concentrations of HDAC8 inhibitors Cpd2 and PCI-48012. The
DLT is defined by loss of body weight of ≥ 20%. Solvent control= 0 mg/kg per day. Data points represent mean values and error bars represent S.E.M. (b) Determination of half-
life of HDAC8 inhibitor Cpd2 in the blood plasma of NMRI Foxn1 nude mice. Cpd2 was injected intraperitoneally at a dose of 100 mg/kg and whole blood was collected at several
time points (0, 10, 20, 30, 45, 60, 75 and 90 min) in cohorts of six animals, respectively. Resulting concentrations were defined by HPLC analysis from blood sera. (c) Western blot
analysis of histone 4 and α-tubulin acetylation levels in PBMC cells of untreated mice (0 h) and respective animals upon treatment with HDAC8 inhibitors PCI-48012 (40 mg/kg)
and Cpd2 (50 mg/kg) 2 h after intraperitoneal injection. Broad-spectrum HDAC inhibitor vorinostat (100 mg/kg) was used as a positive control. Actin served as a loading control.
(d) Growth curve of BE(2)-C neuroblastoma xenografts in nude mice treated intraperitoneally with either solvent, HDAC8 inhibitor PCI-48012 (40 mg/kg per day) or unselective
HDAC inhibitor vorinostat (150 mg/kg per d) in cohorts of 12 animals each. Treatment started 7 days after implantation of tumors (black arrow). Data are represented as mean
tumor volume±S.E.M. A mixed linear model with fixed slope for each group and random intercept for each mouse was used for statistical analysis (SAS ProcMixed)
(*P= 0.0216; **P= 0.0015; ***Po0.0001). (e) Growth curve of IMR-32 neuroblastoma xenografts in nude mice treated intraperitoneally with either solvent, HDAC8 inhibitor
PCI-48012 (40 mg/kg per day) or unselective HDAC inhibitor vorinostat (150 mg/kg per day). Treatment started 7 days after implantation of tumors (black arrow). Data are
represented as mean tumor volume± S.E.M. A mixed linear model with fixed slope for each group and random intercept for each mouse was used for statistical analysis (SAS
ProcMixed) (*P= 0.0349; ***Po0.0001). (f) Changes in body weight of nude mice in a long-term treatment of 3 × 5 days with solvent, HDAC8 inhibitor PCI-48012 (40 mg/kg
per day) and broad-spectrum HDAC inhibitor vorinostat (150 mg/kg per day). Data are represented as mean tumor volume±S.E.M.
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Enhancement of differentiation with combined treatment
of neuroblastoma cells with HDAC8 inhibitor and retinoic
acid in vitro and in vivo. Because we observed induction of
differentiation following selective HDAC8 inhibition, we
wondered whether it is possible to further enhance the
differentiation phenotype via combination with retinoic acid, a
differentiating agent currently in use for neuroblastoma
therapy. In these experiments, we used the HDAC8 inhibitors
in lower concentrations (Cpd2 20 μM and PCI-48000 2 μM),
which were still sufficient to inhibit HDAC8 (Supplementary
Table 2). The combined treatment increased the amount of
neurite outgrowths as well as neurite length in neuroblastoma
cell lines (Figures 5a–c and Supplementary Figure S3A) and
increased the expression of neurofilament (Figure 5a and
Supplementary Figure S3A), as well as NTRK1 (Figure 5d).
Additionally, the combined treatment decreased cell numbers
(Supplementary Figures S3B–D) and the ability to form
colonies in longer-term assays (Figure 5e and Supplementary
Figure S3E). One already well-known result of retinoic acid
treatment in neuroblastoma is the reduction of MYCN
oncogene expression in amplified tumors.21 Interestingly,
the cotreatment with HDAC8-selective inhibitors even further
reduced MYCN protein levels in BE(2)-C and IMR-32 cells
(Figure 5f and Supplementary Figure S3F).
In addition, we combined HDAC8-selective inhibitor
PCI-48012 with retinoic acid in vivo. For these experiments,
the clinically approved drug 13-cis retinoic acid (13-cis RA)
was used instead of ATRA because of its prolonged in vivo
half-life in comparison with ATRA.22 We first determined a
tolerable combination regimen of HDAC8 inhibitor plus retinoic
acid. HDAC8 inhibitor PCI-48012 (40mg/kg per day) was
injected intraperitoenally in combination with 13-cis RA at
different concentrations into NMRI nude mice. Toxicity of the
combination was assessed by monitoring body weight
(Supplementary Figure S4A). These experiments revealed a
tolerable dose for 13-cis RA of 10mg/kg per day, as
intraperitoneal administration in a dose of 20mg/kg per day
caused severe swelling of the abdomen. Treatment of BE(2)-C
xenografted NMRI nude mice for 2 × 5 days with HDAC8
inhibitor, or 13-cis RA revealed that the treatment with HDAC8
inhibitor alone was more potent to reduce tumor growth than
13-cis RA treatment alone. The combination of both agents
was more potent than either treatment alone and resulted in
synergistic effects, which was determined using log-
transformed tumor volumes with a linear mixed model
(Figure 6a and Supplementary Figure S4B). The in vivo
combination of PCI-48012 and 13-cis RA decreased tumor
proliferation and increased tumor cell death in comparison
with either single treatment alone (Figure 6b). In summary,
HDAC8-selective inhibition enhanced antineuroblastoma
activity of retinoic acid treatment in vitro and in vivo.
Forced HDAC8 overexpression counteracts retinoic acid-
mediated differentiation. Next, we used stably HDAC8-
overexpressing BE(2)-C cells for longer-term colony assays
(18 days), and treated the cells with ATRA. During this time
period, untreated cells (HDAC8 and empty vector control)
grew to a high density and began to detach, and thus the
differences were not visible anymore. However, reseeding of
detached cells floating in the supernatant into new
plates revealed a substantial difference between HDAC8-
overexpressing and empty vector control cells (Figure 7a,
labeled as ‘supernatant’). In addition, ATRA efficiently
reduced the ability of empty vector control cells to form
colonies and significantly more colonies were formed by
ATRA-treated HDAC8-overexpressing cells (Figure 7a), sug-
gesting a direct mechanistic link between HDAC8 and retinoic
acid signaling. With this in mind, we focused on CREB,
because CREB is involved in both retinoic acid23 and HDAC8
signaling (Figure 7b). HDAC8 has been described to be
involved in the phosphatase-mediated inactivation of
CREB.24 Indeed, stably HDAC8-overexpressing BE(2)-C
cells displayed lower levels of phosphorylated CREB
(Figure 7c). In addition, expression of tyrosine hydroxylase,
Table 1 Mean indicated values of blood parameters from HDAC8-inhibitor-treated NMRI Foxn1 nude mice (±S.D.) at MTD concentrations in comparison with normal
range
Solvent (n=8) Cpd2 (n= 8) PCI-48012 (n= 8) Normal range (n= 12)
Sodium 133.1±8.9 136.8± 5.3 138.9±5.3 123.4–135.7mmol/l
Potassium 5.8±0.9 6.9± 2.2 6.4±2.2 3.8–6.4 mmol/l
Calcium 2.3±0.1 2.4± 0.4 2.4±0.2 2.1–2.4 mmol/l
Chloride 101.9±3.9 99.9± 2.2 102.0±3.7 97.3–109.7 mmol/l
Creatinine 0.2± .04 0.2± 0.04 0.2±0.02 0.1–0.3 mmol/l
Phosphate 2.6±0.5 1.4± 1.0 1.9±1.2 2.0–2.9 U/l
Urea 26.3±4.2 23.5± 6.4 30.0±7.2 17.4–38.3mg/dl
Uric acid 0.8±0.8 0.9± 1.0 0.7±0.3 0.4–3.2 mg/dl
Glucose 203.9±28.0 187.8± 39.1 174.0±18.6 176.8–238.6 mg/dl
GOT/AST 110.0±5.2 100.3± 46.9 167.5±93.0 68.3–308.7mg/dl
GPT/ALT 66.4±30.1 66.5± 10.9 127.3±73.3 29.8–143.8mg/dl
AP 98.6±26.5 123.8± 35.8 81.8±33.7 62.5–117.6 U/l
GGT − 3.0±1.8 −2.0± 1.0 0.5±0.5 −1.9 to 1.0 U/l
Bilirubin total o0.2 o0.2 o0.2 o0.2 U/l
Leukocytes 3.0±1.0 4.4± 1.8 4.5±1.3 1.8–6.1/nl
Erythrocytes 7.6±0.3 7.6± 0.3 7.0±0.9 5.5–8.2/pl
Thrombocytes 641.0±61.4 682.0± 151.1 690.9±253.1 242.5–806.8/nl
Hemoglobin 12.6±0.7 12.4± 0.7 11.6±1.6 9.4–12.7 g/dl
Hematocrit 0.4±0.02 0.4± 0.01 0.4±0.04 0.3–0.4 l/l
Abbreviations: AP, alkaline phosphatase; GGT, gamma-glutamyltransferase (gammaGT); GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic
transaminase
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which has been described to be regulated by CREB via direct
promoter activation (Armstrong et al.25 and references
therein), was repressed in stably HDAC8-overexpressing
BE(2)-C cells (Figure 7d). Thus, we hypothesize that HDAC8
and ATRA signaling partly converge at the level of CREB and
the combined treatment of neuroblastoma cells with HDAC8
inhibitors and retinoic acid enhances differentiation.
Discussion
The treatment outcome of high-risk neuroblastoma tumors still
needs to be improved. Ongoing studies focus on the
identification of novel therapeutic approaches aiming at
oncogenic molecular targets to improve therapy efficacy for
stage 4 patients.26,27 The use of HDAC inhibitors is emerging
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Figure 3 Phenotype characterization of HDAC8 inhibitors in vitro. (a) Flow cytometric quantitative analysis of neurofilament protein expression. BE(2)-C cells were treated
with HDAC8 inhibitors or solvent for 6 days. Blank (–/–/–/–): secondary antibody only. (b) Western blot analysis of TrkA protein levels. Kelly cells were treated with HDAC8
inhibitors or solvent for 72 h. Actin served as a loading control. (c) Growth curves of BE(2)-C, IMR-32 and Kelly cells treated with HDAC8 inhibitors Cpd2 (40 μM) and PCI-34051
(4 μM). (d) Western blot analysis of p21WAF1/CIP1 protein levels. IMR-32 cells were treated with HDAC8 inhibitors (+) Cpd2 (40 μM), PCI-34051 (4 μM) and PCI-48000 (4 μM) or
solvent (− ) for 72 h. Actin served as a loading control. (e) Time-resolved determination of dead cells via automated cell counting and trypan blue staining (% trypan blue positive)
in IMR-32 cells after treatment with HDAC8 inhibitors; data points represent mean values and error bars represent S.E.M.
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as an effective treatment strategy for cancer therapy.28,29
Several HDAC inhibitors are being tested in phase I–III clinical
trials and show significant responses in leukemias and
lymphoma. Most HDAC inhibitors block the activity of multiple
HDAC isozymes involved in numerous biological processes,
as demonstrated by the loss of function studies in mice. For
example, the knockout of class I HDACs 1 and 3 manifests in
early embryonic lethality in mice and depletion of HDAC2
results in lethal cardiac hypertrophy.30–32 Simultaneous
inhibition of the activity of these HDACs yields a high potential
for toxicities that result in dose-limiting side effects, restricting
the full anticancer potential of HDAC inhibitors. Hence,
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Figure 4 Phenotype characterization of HDAC8 inhibitors in vivo. Shown are representative pictures from tumors of HDAC8-inhibitor-treated animals (PCI-48012 40 mg/kg
per day) and solvent-treated animals. H&E-stained sections, magnification ×400. Neurofilament (brownish color); bar chart reflects the quantitative analysis of neurofilament-
positive tumors (percentage). The quantification was carried out blinded to the treatment. Phosphorylated histone H3-positive cells (brownish color); bar chart reflects the
quantitative analysis of phospho-histone H3-positive cell numbers; t-test was used for statistics; bars represent mean values of 60 pictures (12 tumors per treatment and 5
pictures per slide) and error bars represent S.D. Active caspase-3 (brownish color); bar chart reflects the quantitative analysis of caspase-3-positive cell numbers; t-test was used
for statistics; bars represent mean values, error bars represent S.D. Scale bars= 100 μm. Different regions are shown for the different stainings
Figure 5 Combined treatment of neuroblastoma cells with HDAC8 inhibitors and retinoic acid in vitro. (a) Representative pictures showing crystal violet-stained BE(2)-C cells
6 days after treatment with HDAC8 inhibitors Cpd2 (20 μM) or PCI-34051 (2 μM) and ATRA (10 μM) (scale bar= 200 μm). Immunofluorescent pictures show neurofilament (red)
and DAPI (blue) staining of BE(2)-C cells 6 days after treatment with HDAC8 inhibitors Cpd2 (20 μM) or PCI-34051 (2 μM) and ATRA (10 μM) (scale bar= 100 μm). (b) Bar chart
reflects the quantitative analysis of the number of neurites per cell of BE(2)-C cells. The quantification was carried out blinded to the treatment. T-test was used for statistics
(*Po0.05, **Po0.01 and ***Po0.001). Bars represent mean values and error bars represent S.D. (c) Bar chart reflects the quantitative analysis of the number of neurites per
cell of IMR-32 cells. T-test was used for statistics (*Po0.05, **Po0.01 and ***Po0.001). Bars represent mean values and error bars represent S.D. (d) Bar diagram displays
NTRK1mRNA expression 6 days after treatment of BE(2)-C cells with HDAC8 inhibitors Cpd2 (20 μM) and PCI-48000 (1 μM) in combination with ATRA (10 μM). (e) Longer-term
colony assay of BE(2)-C cells treated once with HDAC8 inhibitors Cpd2 (C; 20 μM) and PCI-34051 (P; 2 μM), and ATRA (A; 10 μM) for at least 10 days. Results were quantified
and are displayed in the bar diagram. Bars represent mean values and error bars represent S.E.M. (***Po0.001). (f) Western blot analysis of MYCN protein levels in BE(2)-C
cells 6 days after treatment with HDAC8 inhibitors Cpd2 (20 μM) or PCI-34051 (2 μM) and ATRA (10 μM)
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inhibition of one single HDAC isozyme could be more effective
and less toxic than the unspecific inhibition of several HDAC
family members by creating a larger therapeutic window. This
study demonstrates superiority of selective HDAC isozyme
targeting versus pan-HDAC inhibition in terms of toxicity and
efficacy in a tumor model that is dependent on HDAC8.
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We chose HDAC8-selective targeting in neuroblastoma for
this direct comparison since in our previous studies we
observed a particular oncogenic function of HDAC8 in
neuroblastoma among all HDAC family members investigated:
advanced-stage and metastasized neuroblastoma tumors
express high levels of HDAC8.15 Here, we demonstrate the
antineuroblastoma efficacy of an HDAC8 inhibitor in vivo at
concentrations avoiding unspecific and therapy-limiting side
effects. Vorinostat has been reported to inhibit primarily
HDACs 1, 2, 3 and 6,33 which are the ubiquitously expressed
HDAC family members that are hypothesized to be respon-
sible for unwanted side effects.10 In contrast, HDAC8
expression has been found to be rather tissue-specific.34
Thus, in terms of unspecific side effects, the targeting of one
single enzyme seems to be superior to pan-HDAC inhibition
when applied in an appropriate tumor entity that displays
oncogenic dependency on that particular HDAC family
member. Nevertheless, besides HDAC8, other HDAC family
members also control tumor-suppressive functions in neuro-
blastoma. For example, HDAC1 in the sensitization of
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Figure 6 Combined treatment with HDAC8 inhibitors and retinoic acid in vivo. (a) Left panel: Growth curves of BE(2)-C neuroblastoma xenografts in NMRI Foxn1 nude mice
treated i.p. with HDAC8 inhibitor PCI-48012 (40 mg/kg/d), 13-cis retinoic acid (10 mg/kg/d) or combination of both compounds. Cohorts consisted of 12 animals each. Treatment
started 7 days after implantation of tumors (black arrow). Data are presented as mean tumor volume± S.E.M.. Right panel: For assessment of in vivo effects, tumor volumes were
log-transformed. A linear mixed model was used with fixed effect for slope in each group and random intercept for each mouse. Statistical analysis of additive or synergistic effects
was performed using SAS Proc Mixed by evaluation of the interaction effect. The right panel shows the predicted change of log tumor volumes over time, displayed as straight
lines with group-specific slope. The red line shows the hypothetical change of log tumor volume if the combinational treatment was additive. Synergistic effects produce a line
below the red line. *Po0.05, ***Po0.001. (b) Immunohistological analysis of tumor material. Shown are representative pictures from tumors of animals treated with either
HDAC8-inhibitor, 13-cis retinoic acid or the combination of both compounds. Hematoxylin & eosin (H&E) stained sections, magnification 400x. Phosphorylated histone H3-positive
cells were counted and quantified as a percent of cells per image; t-test was used for statistics (*Po0.05, **Po0.01). Active caspase-3 (brownish color); bar chart reflects the
quantitative analysis of caspase-3 positive cell numbers; t-test was used for statistics; bars represent mean values, error bars represent S.D. Scale bars= 100 μm. Different
regions are shown for the different stainings
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multidrug-resistant neuroblastoma cell lines to cytotoxic
agents,35 HDAC2 in repressing miR-183-mediated tumor
suppression36 and HDAC3 in negatively regulating tumor
suppressor GRHL1.37 Recently, we have discovered a novel
function for HDAC10 in promoting autophagy-mediated cell
survival. HDAC10 depletion in neuroblastoma cells interrupted
autophagic flux and induced accumulation of autophago-
somes, lysosomes and a substrate of the autophagic
degradation pathway, p62/SQSTM1. Disrupted autophagy
was associated with sensitization to cytotoxic drug treatment
in a panel of highly malignant neuroblastoma cell lines.38
Our experiments also focused on the understanding of the
molecular function of HDAC8 in neuroblastoma to find
rationally targeted treatment combinations for clinical
application of HDAC8-selective inhibitors. So far, HDAC8
has been reported to have specific function in the development
of cranial neural crest cells of mice, as knockout of HDAC8
leads to skull instability and perinatal death.39 Recently,
human HDAC8 variants have been described, which are
associated with X-linked intellectual disability disorders. All
males that carried the variant in HDAC8 showedmicrocephaly
and distinct focal deformation of the skull.39 HDAC8 itself has
been described to be regulated by SOX4,40 a transcription
factor of the SOX family, which is required for B-lymphocyte
development,41 and also during development of the sympa-
thetic nervous system.42,43
The identification of HDAC8-specific substrates is still of
major interest and would be the best tool for HDAC8 inhibitor
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Figure 7 HDAC8 overexpression counteracts ATRA treatment. (a) Longer-term colony assay (18 days) of BE(2)-C cells stably overexpressing HDAC8, treated with ATRA
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on-target validation in tumor tissue. Quite recently, the
cohesion complex protein SMC317 and the tumor suppressor
ARID1A44 have been described to be deacetylated in an
HDAC8-dependent manner. Additionally, HDAC8 has been
linked to phosphatase PP1-mediated CREB inactivation.24
Activation of CREB during ATRA treatment has been
described before45 and phosphorylation of CREB has been
postulated to mediate retinoic acid-induced caspase-8
expression in neuroblastoma cells.23 Caspase-8 is frequently
inactivated by epigenetic silencing in many tumors, including
neuroblastomas, and the expression was induced by the use
of epigenetically acting compounds in combination with
interferon-γ.46 As RA treatment has been described to activate
CREB andHDAC8 expression inactivates CREB, we hypothe-
size that the combined treatment with RA and HDAC8
inhibitors might synergistically act on CREB-mediated cell
differentiation. Indeed, our data show that a combination of
both HDAC8 inhibitor and 13-cis retinoic acid, a currently
applied drug in neuroblastoma treatment protocols, strongly
enhanced differentiation in cell culture and decreased tumor
growth in vivo. Mechanistically, HDAC8 counteracts retinoic
acid-mediated CREB signaling and inhibition of clonogenic
growth and combined treatment with HDAC8 inhibitor and
ATRA enhance CREB phosphorylation. This suggests that the
molecular action of both compounds converge at the level of
CREB. However, the effects on CREB phosphorylation were
rather modest and further experiments are required to unravel
completely the link between retinoic acid and HDAC8 inhibitor
combination treatment-induced cell death and differentiation
mechanism in neuroblastoma.
Taken together, our data demonstrate effectiveness of an
HDAC-selective inhibitor in a preclinicalmodel of neuroblastoma.
Froma clinical perspective, combination of HDAC8 inhibitionwith
retinoic acid treatment might be a promising strategy in the
maintenance treatment of high-risk neuroblastoma.
Materials and Methods
Cell culture and transfections. All cell lines were grown under standard
conditions as described previously.38 Human neuroblastoma cell lines BE(2)-C
(ECACC, Salisbury, UK), IMR-32 (DSMZ, Braunschweig, Germany), Kelly (DSMZ),
SH-SY5Y (DSMZ), SK-N-AS and SH-EP (both generously provided by the
laboratory of M Schwab), and medulloblastoma cell lines UW-228-2, DAOY and
ONS7647 were grown under standard conditions in DMEM with L-glutamine, 4.5 g/l
glucose (Lonza, Basel, Switzerland) and 1% non-essential amino acids (NEAA)
(Invitrogen, Darmstadt, Germany), or RPMI1640 with L-glutamine (Lonza) and 1%
NEAA, or EMEM with L-glutamine. All media were supplemented with 10% fetal
bovine serum (FBS) (Sigma, Munich, Germany). Non-transformed, proliferatively
active primary human skin fibroblasts from an infant donor were a friendly gift from
Petra Boukamp, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Fibroblasts were maintained in DMEM/HAM´s F12 (Invitrogen), supplemented with
10% FBS and 1% NEAA. Neuroblastoma cell lines were last genotyped in April
2012 (DSMZ). Medulloblastoma cell lines were last genotyped in October 2012
(DKFZ). All cell lines were routinely tested for mycoplasma contamination. Human
infant astrocytes (obtained from S Pfister, German Cancer Research Center
(DKFZ)) were grown as described previously.38
Transient transfections were performed as described previously.15 The following
siRNAs were used: HDAC8 (siRNA1 (ID 120597, exons 1 and 2; Ambion
(Huntingdon, UK) Ltd)) and corresponding negative control siRNA (Silencer Negative
Control 1; Ambion).
Generation of stable cell lines: Human BE(2)-C cell lines stably expressing
HDAC8 were established by transfection using Effectene (Qiagen, Hilden, Germany)
with pCEP4/hygro-FLAG HDAC8 cDNA or hygromycin-resistant empty vector
control (pCEP4/hygro-FLAG). Transfected cells were selected with hygromycin
(400 μg/ml) for 3 weeks. A mixed population of hygromycin-resistant cells was used
for experimental analysis.
Animal studies
Mouse xenograft studies with HDAC8 knockdown: BE(2)-C cells
transiently transfected with siRNA against HDAC8 or negative control were
resuspended in Matrigel (BD, Franklin Lakes, NJ, USA) and 20 U/ml heparin 48 h
after transfection. Next, 1.3 × 106 viable cells were implanted in 100 μl Matrigel into
the subcutaneous tissue of right flank of 5- to 6-week-old female athymic nude mice
(NMRI Foxn1; Harlan Laboratories Inc., Nijmegen, The Netherlands) in cohorts of
20 animals each. Cell numbers were established via trypan blue exclusion. Tumor
dimensions were measured and tumor volume (mm3) was calculated as
(L ×W2) × π/6 (L indicating length, W indicating width (all in mm)). At days 3, 6
and 9 after tumor cell injection, three randomly selected mice from each group were
killed, and tumors were explanted. Specimens used for isolation of total RNA or
protein were shock frozen in liquid nitrogen immediately after removal and stored at
− 80 °C. A part of each tumor sample was formalin fixed and embedded in paraffin
for immunohistochemical analysis. The transfection efficiency of siRNA in BE(2)-C
cells was 90% as determined by fluorescently labeled siRNA siGLO Lamin A/C
(Dharmacon, Lafayette, CO, USA).
Preparation of PBMC cells: Whole blood (100 μl) was collected from the
femoral vein of untreated athymic NMRI nude mice (HsdCpb:NMRI-Foxn1nu; Harlan
Laboratories Inc.), and respective animals were killed 2 h after intraperitoneal
injection of substances. For the analysis of whole acetylation levels, mice were killed
at half-life time of the inhibitors. Whole blood with heparin was added to RBC lysis
buffer (diluted 1 : 10) (BioLegend, San Diego, CA, USA) at a ratio of 1 : 4. Next, red
blood cell lysis was performed according to the manufacturer's instructions. PBMCs
were lysed in SDS lysis buffer for western blot or processed for FACS analysis.
Determination of inhibitor plasma half-life: To determine the half-life of
HDAC8 inhibitor Cpd2 in vivo, the substance was injected intraperitoneally at a dose
of 100 mg/kg into athymic NMRI nude mice (Harlan). Whole blood (100 μl) was
collected from the femoral vein of animals at time points 0, 5, 10, 15, 20, 30, 45, 60,
75 and 90 min after injection (six animals per time point). Plasma was obtained by
centrifugation at 10 000 r.c.f. for 10 min at 4 °C and stored at − 80 °C. Plasma
samples (50 μl) were analyzed for Cpd2 concentration after liquid/liquid extraction with
tert.-butylmethylether using HPLC coupled to tandem mass spectrometry (LC/MS/MS;
TSP 2000, TSQ 7000; Thermo Fisher Scientific, Waltham, MA, USA). The extracts
were gradient chromatographed on a Hydro-RP column (4 μM, 150 × 2.1 mm2;
Phenomenex, Torrance, CA, USA) at 40 °C using 5 mM ammonium acetate and
acetonitrile at 0.6 ml/min. The eluent was directly infused into the electrospray ion
source (negative ions) of the MS/MS system and the mass transitions of Cpd2 (m/z
186.1→ 142.0 and m/z 186→ 58.0) and vorinostat (internal standard; m/z
268.1→ 97.0) were monitored in the multiple reaction monitoring mode. Cpd2 and
vorinostat eluted within 6 min and the respective peak area ratios were used for the
quantification of Cpd2 using linear regression in the calibrated range from 100 to
20 000 ng/ml. The limit of quantification was 100 ng/ml and the correlation coefficient
was 40.99. Accuracy and precision control using quality control samples revealed
deviation consistently below 15%, which is in accordance with the FDA guideline,
Guidance for Industry: Bioanalytical Method Validation. All animal studies were
approved by the German Cancer Research Center (DKFZ) institutional animal care
and use committee and the Regional Administrative Council Karlsruhe, Germany. All
experiments were in accordance with the relevant regulatory standards.
Determination of MTD: HDAC8-selective inhibitors were intraperitoneally
injected into athymic NMRI nude mice (Harlan) in increasing doses from 40 to
400 mg/kg per day. DLTs were monitored by observation of general condition and
determination of body weight. We used several criteria for objectively measuring
DLT. These included a decrease in body weight of ≥ 20% compared with baseline
body weight, blood analysis of standard parameters for clinical chemistry and
hematology (central laboratory of University Hospital Heidelberg, Heidelberg,
Germany) and organ histopathology (formalin-fixed, paraffin-embedded organs), by
H&E stain for the detection of necrosis (Prof. Dr. AD Gruber, Institute for Veterinary
Pathology, Berlin, Germany). These measurements assured lack of toxicities at
MTD concentrations of inhibitors.
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Mouse xenograft studies with HDAC8 inhibitors: Neuroblastoma cells
were resuspended in Matrigel and 20 U/ml heparin. Next, 2 × 106 (BE(2)-C) or
4 × 106 (IMR-32) viable cells were implanted in 100 μl Matrigel into the
subcutaneous tissue of right flank of 5- to 6-week old female athymic nude mice
(Harlan). Mice were randomly assigned to groups of 12 individuals bearing similarly
sized tumors. HDAC8-selective inhibitor PCI-48012 at MTD (40 mg/kg per day) was
dissolved in 90% DMSO (HybriMax; Sigma), 10% PBS and given by intraperitoneal
injection for 2 × 5 days. HDAC inhibitor vorinostat was dissolved in 100% DMSO and
given by intraperitoneal injection at a concentration of 150 mg/kg per day for
2 × 5 days. 13-Cis retinoic acid (Sigma) was dissolved in 90% DMSO, 10% PBS and
given by intraperitoneal injection at a concentration of 10 mg/kg per day for
2 × 5 days. Tumor volume (mm3) was calculated as described above (L ×W ×H) ×
π/6, where L indicates length, W indicates width and H indicates height (all in mm)).
At explantation, tumor material was processed as described above.
All animal studies were approved by the German Cancer Research Center (DKFZ)
institutional animal care and use committee and the Regional Administrative Council
Karlsruhe, Germany. All experiments were in accordance with the relevant regulatory
standards.
Reagents. HDAC8-selective inhibitors Cpd213 (stock concentration 250 mM),
PCI-34051 (Figure 2a)14 (stock 20 mM; Pharmacyclics Inc., Sunnyvale, CA, USA),
PCI-48000 (stock 20 mM; Pharmacyclics) and PCI-48012 (Pharmacyclics), as well
as unselective HDAC inhibitors vorinostat (SAHA: suberoylanilide hydroxamic acid)
(stock 100 mM; Selleck Chemicals, Houston, TX, USA) and TSA (stock 1 mM;
Merck, Darmstadt, Germany), were dissolved in DMSO. Cpd2, PCI-34051, and
PCI-48000 were used in in vitro experiments. For in vivo experiments, PCI-48012
was applied. PCI-48000 and PCI-48012 are chemical modifications of PCI-34051
with similar HDAC8 selectivity profiles and similar IC50 values, but longer plasma
half-life in the case of PCI-48012. All-trans retinoic acid (stock 10 mM; Sigma) was
dissolved in ethanol.
In vitro HDAC activity assay. The inhibitory activity of HDAC8-selective
inhibitors towards all classical 1–11 HDACs was investigated by Reaction Biology
Corporation (Malvern, PA, USA). The catalytic domains of human HDACs were
expressed by baculovirus expression system in Sf9 cells. Enzymes were stored in
50 mM Tris-HCl (pH8.0), 138 mM NaCl, 20 mM glutathione and 10% glycerol, and
were stable for46 months at − 80 °C. The purity was ascertained by SDS-PAGE.
Peptide substrate was conjugated with AMC. Reaction buffer was 25 mM Tris-Cl,
pH8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2 and 0.1 mg/ml BSA. The HDAC
reaction was performed at 30 °C for 2 h before adding the developer reagent. The
free AMC was detected with excitation of 360 nm and emission 460 nm at kinetic
mode for 90 min. IC50 values were calculated with GraphPad Prism version 3.0a
(GraphPad Software Inc., San Diego, CA, USA).
Cell counting, cell viability, cell death and colony assay. Cells were
collected, pooled with corresponding supernatant, centrifuged and resuspended in
1.5 ml cell culture media. Cell count as well as cell viability was measured by
automated trypan blue staining with Vi-Cell XR Cell Viability Analyzer from Beckman
Coulter (Krefeld, Germany). Caspase-3-like protease activity assay was performed
as described previously.15
Colony assay. In six-well plates, 500 cells were seeded and treated as
indicated. Viable colonies were stained after a minimum of 10 days with crystal
violet. For quantification, the mean intensity of each well of the 8-bit binary picture
was measured with ImageJ software (U. S. National Institutes of Health, Bethesda,
MD, USA; http://imagej.nih.gov/ij/).
Real-time, reverse-transcription polymerase chain reaction. Real-
time PCR was performed as described previously.15 Data were normalized against
housekeeping genes SDHA and HPRT 48 and set in relation to negative control.
Western blot analysis. Western blot analysis was performed as described
previously.15 For detection of phosphoproteins, PhosStop (Roche, Penzberg,
Germany) was added to the lysis buffer. The following antibodies were used for
detection: anti-HDAC8 (H-145) (polyclonal; Santa Cruz, Santa Cruz, CA, USA), anti-
acetyl tubulin (clone 6-11B-1; Sigma), anti-acetyl-histone H4 (polyclonal; Upstate,
Lake Placid, NY, USA), anti-acetyl-SMC3 (provided by Prof. K Shirahige, University
of Tokyo, Tokyo, Japan), anti p21waf1/cip1 (clone CP74; Merck), anti-Trk (C-14)
(polyclonal; Santa Cruz), anti-neurofilament-M (polyclonal; Merck), anti-β-actin
(clone AC-15; Sigma), anti-P-CREB (Ser133; Cell Signaling, Danvers, MA, USA),
anti-CREB (48H2; Cell Signaling) and anti-GAPDH (clone 6C5; Merck).
Intracellular protein quantification via FACS. Cells were collected,
washed with PBS and fixed with 2% paraformaldehyde for 15 min at room
temperature (RT). Cells were permeabilized by incubation with 50 μg/ml digitonin for
6 min at RT. Cells were incubated with primary antibody overnight at 4 °C. After
staining with Cy3-conjugated anti-rabbit antibody, cells were analyzed by FACS
using CellQuest software (BD Biosciences, San Jose, CA, USA). The following
primary antibodies were used: anti-acetylated lysine (polyclonal; Cell Signaling) and
anti-neurofilament-M (clone EP2460; Epitomics, Burlingame, CA, USA).
Crystal violet staining. Cells were fixed with 2% paraformaldehyde for
15 min at RT. After washing with PBS, sterile filtered crystal violet (0.005% in H2O)
was added for 1 h at RT. Cells were washed three times with H2O. Morphometrical
studies were performed on the photomicroscope CKX41 (Olympus, Hamburg,
Germany) and analyzed with cellB software (Olympus).
Immunohistochemistry. Immunohistochemical stainings were performed
semiautomatically on 5-μM-thick sections of formalin-fixed, paraffin-embedded
specimens using VENTANA Benchmark XT (Strasbourg, France). The following
antibodies were applied according to the manufacturer's protocols: anti-
neurofilament protein (Clone2F11; DakoCytomation, Hamburg, Germany; diluted
1 : 200), anti-phospho-histone H3 (Ser10) (polyclonal; Biocare Medical, Concord,
CA, USA; diluted 1 : 100), anti-active caspase-3 (polyclonal; Abcam, Cambridge,
UK; diluted 1 : 100). Antigen retrieval was performed before primary antibody
exposure. Primary antibody binding sites were visualized using the Ultra-View
Universal DAB Detection Kit (Ventana/Roche, Mannheim, Germany). Nuclei were
automatically counterstained by hematoxylin and blueing reagent (Ventana). From
each specimen, five representative digital images of neurofilament, phosphohistone
H3- and caspase-3-stained sections were captured at × 200 magnification (high
power field, HPF) using a photomicroscope (CKX41; Olympus). Cell imaging
software cellB (Olympus) was used for the acquisition of microscopic images. The
quantification was performed by operators who were blinded to the treatment group
represented in the images. Positive cells were counted with the counting tool of the
cellB software (Olympus). Hematoxylin and eosin (H&E) staining was analyzed at
× 400 magnification (HPF) using photomicroscope Axioskop 2 (Zeiss, Oberkochen,
Germany) equipped with AxioCam ICc1 (Zeiss) and AxioVision Software Release
4.6 (Zeiss).
Statistical analysis. For in vitro experiments, either a two-sided t-test or an
one-way analysis of variance was carried out (SigmaPlot 12.0). Means are
represented in bar charts, and error bars represent the S.D. of at least three
independent experiments. P-values o0.05 were considered significant. For
assessment of in vivo effects, tumor volumes were log-transformed. A linear mixed
model was used with fixed slope for each group and random intercept for each
mouse. Statistical analysis of additive or synergistic effects was performed using
SAS Proc Mixed (Version 9.2; SAS Institute, Cary, NC, USA). Tumor weights were
analyzed with the nonparametric Mann–Whitney test (GraphPad Prism version
3.0a). Error bars represent the S.E.M. P-valueso0.05 were considered significant.
Web-based gene expression analysis: R2 (R2: microarray analysis and
visualization platform; http://r2.amc.nl) was used to investigate HDAC8 expression in
a publically available cohort of primary neuroblastoma patients (Academic Medical
Center (AMC) cohort; Gene Expression Omnibus (GEO) database accession no.
GSE16476). The following probeset was used to detect HDAC8 expression:
223345_at. Patient characteristics were published previously.16
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